The clinical and forensic toxicology of Z-drugs.

Abstract

The Z-drugs zolpidem, zopiclone, and zaleplon were hailed as the innovative hypnotics of the new millennium, an improvement to traditional benzodiazepines in the management of insomnia. Increasing reports of adverse events including bizarre behavior and falls in the elderly have prompted calls for caution and regulation. Z-drugs have significant hypnotic effects by reducing sleep latency and improving sleep quality, though duration of sleep may not be significantly increased. Z-drugs exert their effects through increased γ-aminobutyric acid (GABA) transmission at the same GABA-type A receptor as benzodiazepines. Their pharmacokinetics approach those of the ideal hypnotic with rapid onset within 30 min and short half-life (1-7 h). Zopiclone with the longest duration of action has the greatest residual effect, similar to short-acting benzodiazepines. Neuropsychiatric adverse events have been reported with zolpidem including hallucinations, amnesia, and parasomnia. Poisoning with Z-drugs involves predominantly sedation and coma with supportive management being adequate in the majority. Flumazenil has been reported to reverse sedation from all three Z-drugs. Deaths from Z-drugs are rare and more likely to occur with polydrug overdose. Z-drugs can be detected in blood, urine, oral fluid, and postmortem specimens, predominantly with liquid chromatography-mass spectrometry techniques. Zolpidem and zaleplon exhibit significant postmortem redistribution. Zaleplon with its ultra-short half-life has been detected in few clinical or forensic cases possibly due to assay unavailability, low frequency of use, and short window of detection. Though Z-drugs have improved pharmacokinetic profiles, their adverse effects, neuropsychiatric sequelae, and incidence of poisoning and death may prove to be similar to older hypnotics.

• Authors: Naren Gunja
• Journal: Journal of medical toxicology : official journal of the American College of Medical Toxicology (J Med Toxicol) Vol. 9 Issue 2 Pg. 155-62 (Jun 2013) ISSN: 1937-6995 [Electronic] United States
• PMID: 23404347 (Publication Type: Journal Article, Review)

Chemical References

• Acetamides
• Azabicyclo Compounds
• GABA Modulators
• GABA-A Receptor Agonists
• Hypnotics and Sedatives
• Piperazines
• Pyridines
• Pyrimidines
• zopiclone
• Flumazenil
• Zolpidem
• zaleplon

Topics

• Acetamides (adverse effects, pharmacokinetics, poisoning)
• Azabicyclo Compounds (adverse effects, pharmacokinetics, poisoning)
• Coma (etiology, prevention & control)
• Drug Overdose (drug therapy, mortality, physiopathology)
• Flumazenil (therapeutic use)
• GABA Modulators (therapeutic use)
• GABA-A Receptor Agonists (adverse effects, pharmacokinetics, poisoning)
• Humans
• Hypnotics and Sedatives (adverse effects, pharmacokinetics, poisoning)
• Piperazines (adverse effects, pharmacokinetics, poisoning)
• Pyridines (adverse effects, pharmacokinetics, poisoning)
• Pyrimidines (adverse effects, pharmacokinetics, poisoning)
• Zolpidem